Taylor Wessing advised Cumulus Oncology Cumulus Oncology on its exclusive GPR68 licence and development collaboration with leadXpro. Cumulus Oncology and leadXpro initiated a groundbreaking collaboration in...
You must be a Standard 1 Year member to access this content.
Taylor Wessing advised Apollo Therapeutics on its series C funding round. Apollo Therapeutics Limited, a biopharmaceutical company headquartered in Cambridge, has successfully raised $226.5 million in...
You must be a Standard 1 Year member to access this content.
Taylor Wessing advised Shield Therapeutics plc on the deal. Shield Therapeutics plc, an AIM-listed commercial stage specialty pharmaceutical company, concluded its transformational collaboration agreement with global...
You must be a Standard 1 Year member to access this content.
Taylor Wessing advised Nuclera on the deal. Nuclera, the pioneer in making biology accessible to everyone through desktop bioprinting, thorugh its Series B financing, raised a...
You must be a Standard 1 Year member to access this content.
Sullivan & Worcester advised E Ink on the deal. Taylor Wessing advised Nuclera. E Ink, the leading innovator of electronic ink technology, announced the sale of its...
You must be a Standard 1 Year member to access this content.
